文献速递临床试验与 GCP

甲泼尼龙作为血管内取栓辅助治疗大血管闭塞性卒中的MARVEL随机临床试验

Methylprednisolone as Adjunct to Endovascular Thrombectomy for Large-Vessel Occlusion Stroke: The MARVEL Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01

MARVEL随机双盲安慰剂对照试验在中国82家医院纳入1680例发病24小时内的大血管闭塞性卒中患者,比较甲泼尼龙2 mg/kg/d或安慰剂连用3天辅助血管内取栓的疗效与安全性。结果显示甲泼尼龙未显著改善90天改良Rankin量表整体分布,但死亡率(23.2% vs 28.5%)和症状性颅内出血率(8.6% vs 11.7%)低于安慰剂组。

要点

  • 甲泼尼龙辅助取栓未显著改善90天改良Rankin量表整体分布。
  • 甲泼尼龙组90天死亡率低于安慰剂组(23.2% vs 28.5%)。
  • 甲泼尼龙组48小时内症状性颅内出血率低于安慰剂组(8.6% vs 11.7%)。

核心结论

  • 在大血管闭塞所致急性缺血性卒中接受血管内取栓的患者中,辅助甲泼尼龙未显著改善整体残疾程度。

研究设计与样本

  • 由研究者发起的随机双盲安慰剂对照试验,在中国82家医院实施。
  • 纳入1680例发病24小时内的大血管闭塞性卒中患者,随机分为甲泼尼龙组(n=839)和安慰剂组(n=841)。
  • 招募时间为2022年2月9日至2023年6月30日,最终随访日期为2023年9月30日。
  • 干预为静脉甲泼尼龙2 mg/kg/d或安慰剂,连用3天,均辅助血管内取栓。

主要发现

  • 90天改良Rankin量表评分中位数甲泼尼龙组为3(IQR 1-5),安慰剂组为3(IQR 1-6),校正广义优势比为1.10(95%CI 0.96-1.25;P=0.17)。
  • 90天死亡率甲泼尼龙组为23.2%,安慰剂组为28.5%,校正风险比为0.84(95%CI 0.71-0.98;P=0.03)。
  • 48小时内症状性颅内出血率甲泼尼龙组为8.6%,安慰剂组为11.7%,校正风险比为0.74(95%CI 0.55-0.99;P=0.04)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It is uncertain whether intravenous methylprednisolone improves outcomes for patients with acute ischemic stroke due to large-vessel occlusion (LVO) undergoing endovascular thrombectomy. OBJECTIVE: To assess the efficacy and adverse events of adjunctive intravenous low-dose methylprednisolone to endovascular thrombectomy for acute ischemic stroke secondary to LVO. DESIGN, SETTING, AND PARTICIPANTS: This investigator-initiated, randomized, double-blind, placebo-controlled trial was implemented at 82 hospitals in China, enrolling 1680 patients with stroke and proximal intracranial LVO presenting within 24 hours of time last known to be well. Recruitment took place between February 9, 2022, and June 30, 2023, with a final follow-up on September 30, 2023. INTERVENTIONS: Eligible patients were randomly assigned to intravenous methylprednisolone (n = 839) at 2 mg/kg/d or placebo (n = 841) for 3 days adjunctive to endovascular thrombectomy. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was disability level at 90 days as measured by the overall distribution of the modified Rankin Scale scores (range, 0 [no symptoms] to 6 [death]). The primary safety outcomes included mortality at 90 days and the incidence of symptomatic intracranial hemorrhage within 48 hours. RESULTS: Among 1680 patients randomized (median age, 69 years; 727 female [43.3%]), 1673 (99.6%) completed the trial. The median 90-day modified Rankin Scale score was 3 (IQR, 1-5) in the methylprednisolone group vs 3 (IQR, 1-6) in the placebo group (adjusted generalized odds ratio for a lower level of disability, 1.10 [95% CI, 0.96-1.25]; P = .17). In the methylprednisolone group, there was a lower mortality rate (23.2% vs 28.5%; adjusted risk ratio, 0.84 [95% CI, 0.71-0.98]; P = .03) and a lower rate of symptomatic intracranial hemorrhage (8.6% vs 11.7%; adjusted risk ratio, 0.74 [95% CI, 0.55-0.99]; P = .04) compared with placebo. CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke due to LVO undergoing endovascular thrombectomy, adjunctive methylprednisolone added to endovascular thrombectomy did not significantly improve the degree of overall disability. TRIAL REGISTRATION: ChiCTR.org.cn Identifier: ChiCTR2100051729.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Yang Q, Guo C, Yue C, et al. Methylprednisolone as Adjunct to Endovascular Thrombectomy for Large-Vessel Occlusion Stroke: The MARVEL Randomized Clinical Trial. JAMA. 2024. PMID: 38329440. doi:10.1001/jama.2024.0626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。